Hepatic MRI with SPIO: detection and characterization of focal liver lesions

A variety of parenterally administered iron oxides have been developed for contrast-enhanced MRI of the liver. Two different classes of iron oxides are currently clinically approved or in phase 3 trials: superparamagnetic iron oxides (SPIO) with a high R2/R1 relaxivity ratio and short blood half-life (AMI-25 and SH U 555 A), and ultrasmall paramagnetic iron oxides (USPIO) with a lower R2/R1 relaxivity ratio and longer blood half-life (AMI-227). All iron oxides significantly increase tumor-to-liver contrast and allow detection of more lesions than unenhanced MRI on T2-weighted images at a field strength of 0.2-1.5 T. Malignant lesions without phagocytic cells exhibit constant signal on T2-weighted accumulation phase images with all three iron oxides. All iron oxides cause a signal decrease of benign lesions with either phagocytic cells or a significant blood pool on T2-weighted accumulation phase images. The signal decrease of benign lesions is proportional to the Kupffer cell activity or tumor vascularity and is useful for lesion characterization. Another enhancement feature for the differentiation of benign from malignant lesions is ring enhancement of malignant lesions (metastases) on T1-weighted enhanced images either during the perfusion phase with SH U 555 A or during the accumulation phase with AMI-227, which is attributed to the blood pool effects of the compounds. Differentiation of lesions and vessels is easier on enhanced images with angiographic effects than on unenhanced images. Iron oxides improve the quality of two-dimensional MR angiography techniques of the portal venous system by decreasing background signal (liver tissue with all iron oxides) and increasing intravascular signal (AMI-227). The use of iron oxides for hepatic MRI provides an alternative to the existing multistep diagnosis with CT, CT portography, MRI and biopsy.